Table 1 Baseline characteristics
Variables | Overall N = 422 | Patients with primary endpoint events N = 333 | Patients without primary endpoint events N = 89 | P-value |
|---|---|---|---|---|
Age, y | 59 ± 11 | 59 ± 11 | 58 ± 12 | 0.989 |
Male, n (%) | 273(64.7) | 208(62.5) | 65(73.0) | 0.064 |
CRT-D, n (%) | 183(43.4) | 138(41.4) | 45(50.6) | 0.123 |
BMI, (kg/m2) | 24.53 ± 4.71 | 24.85 ± 4.93 | 2323 ± 3.46 | 0.006 |
Atrial fibrillation, n (%) | 71(16.8) | 50(15.0) | 21(23.6) | 0.055 |
LBBB, n (%) | 297(70.4) | 250(75.1) | 47(52.8) | < 0.001 |
NYHA class, n (%) | ||||
 II | 128(30.3) | 113(33.9) | 15(16.9) | 0.002 |
 III | 239(56.6) | 187(56.2) | 52(58.4) | 0.701 |
 IV | 55(13) | 33(9.9) | 22(24.7) | < 0.001 |
 Initial QRS width(ms) | 166.92 ± 22.58 | 164.43 ± 23.44 | 168.81 ± 19.03 | 0.065 |
Echocardiography | ||||
 LA(mm) | 44.14 ± 7.41 | 43.38 ± 7.19 | 47.00 ± 7.54 | < 0.001 |
 LVEDD(mm) | 70.09 ± 10.69 | 69.34 ± 10.62 | 72.91 ± 10.52 | 0.005 |
LVEF (%) | 30.45 ± 8.45 | 30.95 ± 8.53 | 28.60 ± 7.91 | 0.020 |
Laboratory factors | ||||
 NT-proBNP (pg/ml) | 2173 ± 2018 | 1912 ± 1798 | 3150 ± 2462 | < 0.001 |
 Uric Acid (umol/L) | 433.65 ± 130.00 | 430.15 ± 124.65 | 446.75 ± 148.35 | 0.285 |
 HsCRP(mg/L) | 2.79 ± 3.89 | 3.21 ± 3.48 | 5.67 ± 4.69 | < 0.001 |
 Creatinine(umol/L) | 90.98 ± 28.69 | 88.65 ± 23.66 | 99.68 ± 41.57 | 0.001 |
 Albumin | 42.13 ± 4.87 | 42.62 ± 4.94 | 40.31 ± 4.15 | < 0.001 |
 AST | 23.41 ± 11.88 | 22.56 ± 10.97 | 26.55 ± 14.42 | 0.005 |
 Big endothelin-1 | 0.55 ± 0.41 | 0.49 ± 0.37 | 0.78 ± 0.45 | < 0.001 |
Medications | ||||
 ACEI/ARB, n (%) | 330(78.2) | 273(82.0) | 57(64.0) | < 0.001 |
 Beta-blockers, n (%) | 384(91) | 304(91.3) | 80(89.9) | 0.681 |
 Diuretics, n (%) | 396(93.8) | 313(94.0) | 83(93.3) | 0.798 |
 Spironolactone, n (%) | 373(88.4) | 299(89.8) | 74(83.1) | 0.082 |